Solid Biosciences Inc.
SLDB
$3.41
$0.113.33%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 25.95% | 259.62% | 116.92% | 30.93% | -2.37% |
| Gross Profit | -25.95% | -259.62% | -116.92% | -46.38% | -8.87% |
| SG&A Expenses | 19.98% | 30.80% | 21.05% | 17.48% | 15.26% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 24.36% | 5.66% | -3.92% | -7.54% | 1.77% |
| Operating Income | -24.36% | -5.66% | 3.92% | 1.89% | -10.50% |
| Income Before Tax | -29.87% | -12.78% | -0.48% | 0.52% | -11.67% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -29.87% | -12.78% | -0.48% | 0.52% | -11.67% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -29.87% | -12.78% | -0.48% | 0.52% | -11.67% |
| EBIT | -24.36% | -5.66% | 3.92% | 1.89% | -10.50% |
| EBITDA | -25.10% | -6.53% | 3.63% | 1.79% | -10.59% |
| EPS Basic | 37.27% | 40.94% | 51.59% | 55.73% | 54.92% |
| Normalized Basic EPS | 37.31% | 47.78% | 55.95% | 57.91% | 56.78% |
| EPS Diluted | 37.24% | 40.92% | 51.57% | 55.71% | 54.89% |
| Normalized Diluted EPS | 37.31% | 47.78% | 55.95% | 57.91% | 56.78% |
| Average Basic Shares Outstanding | 105.27% | 98.89% | 104.96% | 112.79% | 133.57% |
| Average Diluted Shares Outstanding | 105.27% | 98.89% | 104.96% | 112.79% | 133.57% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |